ArticleInternational journal of molecular sciences2025

Zongertinib, a Novel HER2 Tyrosine Kinase Inhibitor, Maintains an Anticancer Activity for Trastuzumab Deruxtecan-Resistant Cancers Harboring HER2-Overexpression.

Takashi Kurosaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.